Fusion Antibodies is a contract research organisation, which designs, and optimizes therapeutic and diagnostic antibodies for both human and animal applications. We help clients solve complex, challenging problems throughout their entire pre-clinical antibody program, including but not limited to antibody discovery, engineering and supply. Our expertise is defined by over a thousand of successful antibody development projects. Facilitated by unique process frameworks, and technology platforms, Fusion enable our clients to develop therapeutics and diagnostics within the most challenging modalities and diseases. With our collaborative approach, we work very closely with biotechs, academic institutions, diagnostic and pharmaceutical organizations towards their end-goals – the provision of treatments or diagnostics that improve the lives of human and animal patients worldwide.
As an independent team, we offer flexibility and agility that antibody discovery and development programs require. Our approach to projects considers long-term impacts on safety, efficacy, and manufacturability at every stage, de-risking antibody programs and maximizing success. As an early discovery partner, our scientists increase the pace to commercialization by guiding clients to develop the best antibodies possible.